Passionate about IP! Since June 2003 the IPKat has covered copyright, patent, trade mark, designs, info-tech and confidentiality issues from a mainly UK and European perspective. Read, post comments and participate!

The team is Eleonora Rosati, Annsley Merelle Ward and Merpel. E-mail the Kats here!

The team is joined by GuestKats Söğüt Atilla, Oliver Fairhurst, Claire Gregg, Georgia Jenkins and Marcel Pemsel.

SpecialKats: Verónica Rodríguez Arguijo (TechieKat), Rose Hughes (PatKat) and Jocelyn Bosse (Book Review Editor).

InternKats: Wissam Bentazar, Simone Lorenzi and Kliment Markov.
Results for exclusions to patentability
Never Too Late: If you missed the IPKat last week! Never Too Late: If you missed the IPKat last week! Reviewed by Asude Sena Moya on Tuesday, August 27, 2024 Rating: 5
Falling between the cracks: The challenges of patent strategy for stem cell therapies (T 1259/22) Falling between the cracks: The challenges of patent strategy for stem cell therapies (T 1259/22) Reviewed by Dr Rose Hughes on Wednesday, August 21, 2024 Rating: 5
The difference between the credibility and the unambiguous disclosure of a therapeutic effect (T 0209/22) The difference between the credibility and the unambiguous disclosure of a therapeutic effect (T 0209/22) Reviewed by Dr Rose Hughes on Sunday, June 02, 2024 Rating: 5
Make no bones about it: The "credibility test" has no place in the novelty assessment of second medical use claims (T 0558/20) Make no bones about it: The "credibility test" has no place in the novelty assessment of second medical use claims (T 0558/20) Reviewed by Dr Rose Hughes on Wednesday, August 30, 2023 Rating: 5
Subscribe to: Posts ( Atom )
Powered by Blogger.